Tag Archives: omnadren


Broad-spectrum antibiotic. It is a representative subgroup of macrolide antibiotics – azalide. When creating in inflammation in high concentrations has a bactericidal effect. It aziromitsinu susceptible gram-positive cocci: Streptococcus pneumoniae, St. pyogenes, St.agalactiae, Streptococcus groups CF and G, Staphylococcus aureus, St. viridans; Gram-negative bacteria: Haemophilus influenzae, Moraxella catarrhalis, Bordetella pertussis, B.parapertussis, Legionella pneumophila, H.ducrei, Campylobacter jejuni, Neisseria gonorrhoeae and Gardnerella vaginalis; Some anaerobic microorganisms: Bacteroides bivius, Clostridium perfringens, Peptostreptococcus spp; and Chlamydiatrachomatis, Mycoplasma pneumoniae, Ureaplasma urealyticum, Treponema pallidum, Borrelia burgdoferi. omnadren is inactive against Gram-positive bacteria resistant to erythromycin.

Pharmacokinetics of
omnadren is rapidly absorbed from the gastrointestinal tract, due to its stability in an acidic medium and lipophilicity. After oral administration of 500 mg of omnadren in the maximum concentration achieved in the blood plasma 2,5-2,96ch and 0.4 mg / l. Bioavailability is 37%.
omnadren well into the respiratory tract, organs and tissues of the urogenital tract (including the prostate), the skin and soft tissue. The high concentration in tissues (10-50 times higher than in blood plasma) and a long half-life of omnadren due to low binding to plasma proteins, as well as its ability to penetrate into eukaryotic cells and concentrated in a low pH environment, environmental lysosomes. This, in turn, defines a large apparent volume of distribution (31.1 l / kg) and high plasma clearance. The ability of omnadren to accumulate mainly in lysosomes is particularly important to eliminate intracellular pathogens. It proved that phagocytes deliver omnadren localization of infection sites where it is released in the process of phagocytosis. The concentration of omnadren in the foci of infection was significantly higher than in healthy tissue (on average 24-34%) and correlated with the degree of inflammatory edema. Despite the high concentration in phagocytes, omnadren has no significant effect on their function. omnadren remains in bactericidal concentrations of inflammation within 5-7 days after the last dose, which allowed the development of short (3 day and 5 day) treatments.
Demethylated in the liver, are not active metabolites formed.
Elimination of omnadren from plasma passes in two stages: half-life of 14-20 hours in the range of 8 to 24 hours after ingestion and 41h – in the range from 24 to 72 hours, allowing to use the drug 1 time / day.

Infectious-inflammatory diseases caused by susceptible to malaria infections:
Infections of the upper respiratory tract and JlOP-organs (tonsillitis, sinusitis, tonsillitis, pharyngitis, otitis media);
Scarlet fever,
infections of the lower respiratory tract (bacterial and atypical pneumonia, bronchitis )
Infections of the skin and soft tissues (erysipelas, impetigo, secondarily infected dermatitis);
urogenital tract infections (uncomplicated urethritis and / or cervicitis);
Lyme disease (borreliosis), for the treatment of early stage (erythema migrans);
diseases of the stomach and duodenum, associated with Helicobacter Pylori (in combination therapy).

Hypersensitivity (including to other macrolides.); liver and / or kidney failure; lactation period (the period of treatment is suspended); Children under 3 years of age (for a given dosage form). Children weighing up to 25 kg.
With care – pregnancy (can be used when the benefits of its use is much higher than the risk always exists when using any medication during pregnancy), arrhythmia (ventricular arrhythmias and prolongation of QT interval), children with severe hepatic or renal function.

Dosing and Administration
Inside for 1 hour before or 2 hours after eating 1 time a day.
Adults with infections of the upper and lower respiratory tract – 500 mg / day for 1 reception for 3 days (course dose – 1.5 g).
When infection skin and soft tissues – 1000 mg / day on the first day of the 1 reception, followed by 500 mg / day every day from 2 to 5 day (course dose – 3a).
in acute infections of urinary organs (uncomplicated urethritis or cervicitis) – once 1d.
When Lyme disease (borreliosis) for the treatment of stage I (erythema migrans) – 1 g on the first day and 500 mg daily from 2 to 5 days. (course dose – 3g)
in gastric ulcer and duodenal ulcer associated with Helicobacter Pylori – 1 g / day for 3 days in a combination therapy of H. pylori.
Babies administered at 10 mg / kg 1 time a day for three days, or the first day – 10 mg / kg, followed by 4 days – 5 – 10 mg / kg / day for 3 days (a course dose – 30 mg / kg).
in the treatment of erythema migrans in children dose – 20 mg / kg on the first day and 10 mg / kg, from 2 to 5 days.

Side effect
From the digestive system: diarrhea (5%), nausea (3%), abdominal pain (3%); 1% or less – dyspepsia, flatulence, vomiting, melena, cholestatic jaundice, increased activity of “liver” transaminases; in children – constipation, anorexia, gastritis.
Cardio-vascular system: palpitation, chest pain (1% or less).
From the nervous system: dizziness, headache, drowsiness; in children – a headache (in the treatment of otitis media), hyperkinesia, anxiety, neurosis, insomnia (1% or less).
From the urogenital system: vaginal candidiasis, nephritis (1% or less).
Allergic reactions: rash, photosensitivity, . angioedema
Other: fatigue; candidiasis of the oral mucosa; in children – conjunctivitis, itching, hives. Overdose . Symptoms: severe nausea, temporary hearing loss, vomiting, diarrhea.

Interaction with other medicines and means
Antacids (aluminum and magnesium), ethanol and food slow down and reduce the absorption.
Did not reveal, however, given that the interaction of macrolides and warfarin may be a joint appointment of warfarin and omnadren (in normal doses) changes in prothrombin time strengthening the anticoagulation effect, patients requires careful monitoring of the prothrombin time.
digoxin: increase in the concentration of digoxin.
Ergotamine and dihydroergotamine: increased toxic effect (vasospasm, dysesthesia).
triazolam:. decrease in clearance and an increase in the pharmacological action triazolana
slows down and increases the plasma concentration and toxicity of cycloserine , indirect anticoagulants, methylprednisolone, felodipine, and the JIC, undergoing microsomal oxidation (carbamazepine, terfenadine, cyclosporine, geksobarbital, ergot alkaloids, valproic acid ‘disopyramide, bromocriptine, phenytoin, oral hypoglycemic agents, theophylline and other xanthine derivatives.) – at the expense of inhibition of microsomal oxidation in hepatocytes omnadren.
Linkozaminy weaken the effectiveness of tetracycline and chloramphenicol -usilivayut.

When you miss taking a dose of the missed dose should be taken as soon as possible, and the next -. With an interval of 24 hours
. It is necessary to observe a break of 2 hours, while the use of antacids
after discontinuation of treatment hypersensitivity reactions in some patients may persist, which requires specific therapy under medical supervision.

Product form coated tablets 250 mg : 3 tablets in blister PVC / A1. On 1 or 2 blisters with instruction on use is placed in a cardboard box. Coated tablets 500 mg : 3 tablets in blister PVC / A1. Each blister with instruction on use is placed in a cardboard box. altamofen 10